Comprehensive Stock Comparison
Compare Crinetics Pharmaceuticals, Inc. (CRNX) vs BioMarin Pharmaceutical Inc. (BMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CRNX | 421.7% revenue growth vs BMRN's 12.9% |
| Quality / Margins | BMRN | 10.8% net margin vs CRNX's -85.9% |
| Stability / Safety | BMRN | Beta 0.74 vs CRNX's 1.05 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CRNX | +14.9% vs BMRN's -13.3% |
| Efficiency (ROA) | BMRN | 4.6% ROA vs CRNX's -41.3%, ROIC 7.4% vs -37.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral therapies for rare endocrine diseases and endocrine-related tumors. It currently generates no revenue from product sales—funding comes from equity offerings and collaborations—but aims to commercialize its lead candidate paltusotine for acromegaly pending regulatory approval. The company's moat lies in its specialized expertise in nonpeptide somatostatin receptor pharmacology and a pipeline targeting underserved endocrine disorders with high unmet medical need.
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. It generates revenue primarily from sales of its orphan drug portfolio — including Voxzogo, Vimizim, and Palynziq — with additional income from licensing and royalties. The company's moat lies in its deep expertise in rare disease biology and its established commercial infrastructure for ultra-orphan drugs, which creates high barriers to entry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BMRN leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). CRNX leads in 1 (Total Returns).
Financial Metrics (TTM)
BMRN is the larger business by revenue, generating $3.2B annually — 594.3x CRNX's $5M. BMRN is the more profitable business, keeping 10.8% of every revenue dollar as net income compared to CRNX's -85.9%.
| Metric | CRNXCrinetics Pharmac… | BMRNBioMarin Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $5M | $3.2B |
| EBITDAEarnings before interest/tax | -$514M | $613M |
| Net IncomeAfter-tax profit | -$465M | $349M |
| Free Cash FlowCash after capex | -$384M | $725M |
| Gross MarginGross profit ÷ Revenue | +108.5% | +77.1% |
| Operating MarginEBIT ÷ Revenue | -95.3% | +16.6% |
| Net MarginNet income ÷ Revenue | -85.9% | +10.8% |
| FCF MarginFCF ÷ Revenue | -70.8% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -47.7% | -134.4% |
Valuation Metrics
| Metric | CRNXCrinetics Pharmac… | BMRNBioMarin Pharmace… |
|---|---|---|
| Market CapShares × price | $3.9B | $11.9B |
| Enterprise ValueMkt cap + debt − cash | $3.9B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | -8.30x | 34.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 18.18x |
| Price / SalesMarket cap ÷ Revenue | 724.75x | 3.68x |
| Price / BookPrice ÷ Book value/share | 3.90x | 2.00x |
| Price / FCFMarket cap ÷ FCF | — | 16.36x |
Profitability & Efficiency
BMRN delivers a 5.7% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-47 for CRNX. CRNX carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to BMRN's 0.10x. On the Piotroski fundamental quality scale (0–9), BMRN scores 5/9 vs CRNX's 2/9, reflecting solid financial health.
| Metric | CRNXCrinetics Pharmac… | BMRNBioMarin Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -46.9% | +5.7% |
| ROA (TTM)Return on assets | -41.3% | +4.6% |
| ROICReturn on invested capital | -37.8% | +7.4% |
| ROCEReturn on capital employed | -42.8% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 0.10x |
| Net DebtTotal debt minus cash | -$53M | -$715M |
| Cash & Equiv.Liquid assets | $102M | $1.3B |
| Total DebtShort + long-term debt | $49M | $597M |
| Interest CoverageEBIT ÷ Interest expense | — | 48.95x |
Total Returns (with DRIP)
A $10,000 investment in CRNX five years ago would be worth $26,195 today (with dividends reinvested), compared to $7,797 for BMRN. Over the past 12 months, CRNX leads with a +14.9% total return vs BMRN's -13.3%. The 3-year compound annual growth rate (CAGR) favors CRNX at 27.9% vs BMRN's -14.7% — a key indicator of consistent wealth creation.
| Metric | CRNXCrinetics Pharmac… | BMRNBioMarin Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -12.0% | +3.8% |
| 1-Year ReturnPast 12 months | +14.9% | -13.3% |
| 3-Year ReturnCumulative with dividends | +109.3% | -38.0% |
| 5-Year ReturnCumulative with dividends | +162.0% | -22.0% |
| 10-Year ReturnCumulative with dividends | +67.7% | -24.6% |
| CAGR (3Y)Annualised 3-year return | +27.9% | -14.7% |
Risk & Volatility
BMRN is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than CRNX's 1.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BMRN currently trades 84.0% from its 52-week high vs CRNX's 70.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRNXCrinetics Pharmac… | BMRNBioMarin Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.05x | 0.74x |
| 52-Week HighHighest price in past year | $57.99 | $73.51 |
| 52-Week LowLowest price in past year | $24.10 | $50.76 |
| % of 52W HighCurrent price vs 52-week peak | +70.9% | +84.0% |
| RSI (14)Momentum oscillator 0–100 | 39.0 | 56.6 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.9M |
Analyst Outlook
Wall Street rates CRNX as "Buy" and BMRN as "Buy". Consensus price targets imply 130.4% upside for CRNX (target: $95) vs 32.8% for BMRN (target: $82).
| Metric | CRNXCrinetics Pharmac… | BMRNBioMarin Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $94.71 | $82.00 |
| # AnalystsCovering analysts | 18 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Crinetics Pharmaceu… (CRNX) | 100 | 239.21 | +139.2% |
| BioMarin Pharmaceut… (BMRN) | 100 | 61.39 | -38.6% |
Crinetics Pharmaceu… (CRNX) returned +162% over 5 years vs BioMarin Pharmaceut… (BMRN)'s -22%. A $10,000 investment in CRNX 5 years ago would be worth $26,195 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Crinetics Pharmaceu… (CRNX) | $589000.00 | $5M | +820.2% |
| BioMarin Pharmaceut… (BMRN) | $1.1B | $0.00 | -100.0% |
Crinetics Pharmaceuticals, Inc.'s revenue grew from $1M (2016) to $5M (2025) — a 28.0% CAGR. BioMarin Pharmaceutical Inc.'s revenue grew from $1.1B (2016) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Crinetics Pharmaceu… (CRNX) | -10.2% | -85.9% | -740.1% |
| BioMarin Pharmaceut… (BMRN) | -56.4% | 15.0% | +126.5% |
Crinetics Pharmaceuticals, Inc.'s net margin went from -10% (2016) to -86% (2025).
Chart 4P/E Ratio History — 5 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 19.4 | 424.5 | +2088.1% |
BioMarin Pharmaceutical Inc. has traded in a 19x–425x P/E range over 5 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Crinetics Pharmaceu… (CRNX) | -0.43 | -4.95 | -1051.2% |
| BioMarin Pharmaceut… (BMRN) | -3.79 | 0.14 | +103.7% |
Crinetics Pharmaceuticals, Inc.'s EPS grew from $-0.43 (2016) to $-4.95 (2025). BioMarin Pharmaceutical Inc.'s EPS grew from $-3.79 (2016) to $0.14 (2025).
Chart 6Free Cash Flow — 5 Years
Crinetics Pharmaceuticals, Inc. generated $-384M FCF in 2025 (-331% vs 2021). BioMarin Pharmaceutical Inc. generated $725M FCF in 2025 (+291% vs 2021).
CRNX vs BMRN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CRNX or BMRN a better buy right now?
BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 34.3x trailing P/E (15.4x forward), making it the more compelling value choice. Analysts rate Crinetics Pharmaceuticals, Inc. (CRNX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRNX or BMRN?
Over the past 5 years, Crinetics Pharmaceuticals, Inc. (CRNX) delivered a total return of +162.0%, compared to -22.0% for BioMarin Pharmaceutical Inc. (BMRN). A $10,000 investment in CRNX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CRNX returned +67.7% versus BMRN's -24.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRNX or BMRN?
By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc. (BMRN) is the lower-risk stock at 0.74β versus Crinetics Pharmaceuticals, Inc.'s 1.05β — meaning CRNX is approximately 40% more volatile than BMRN relative to the S&P 500. On balance sheet safety, Crinetics Pharmaceuticals, Inc. (CRNX) carries a lower debt/equity ratio of 5% versus 10% for BioMarin Pharmaceutical Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CRNX or BMRN?
BioMarin Pharmaceutical Inc. (BMRN) is the more profitable company, earning 10.8% net margin versus -85.9% for Crinetics Pharmaceuticals, Inc. — meaning it keeps 10.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16.6% versus -95.3% for CRNX. At the gross margin level — before operating expenses — CRNX leads at 80.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is CRNX or BMRN more undervalued right now?
Analyst consensus price targets imply the most upside for CRNX: 130.4% to $94.71.
06Which pays a better dividend — CRNX or BMRN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CRNX or BMRN better for a retirement portfolio?
For long-horizon retirement investors, BioMarin Pharmaceutical Inc. (BMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.74)). Both have compounded well over 10 years (BMRN: -24.6%, CRNX: +67.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CRNX and BMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.